Jun 19, 2020
Global Spinal Muscular Atrophy Market Outlook to 2027 - Advent of Oral mRNA Splicer for Treatment
Jun 12, 2020
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy
Apr 30, 2020
PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Apr 28, 2020
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy
Apr 07, 2020
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
Feb 06, 2020
SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy
Feb 03, 2020
PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference
Jan 23, 2020
Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy
Jan 13, 2020
PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference
Dec 24, 2019
Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
Nov 11, 2019
Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy
Sep 30, 2019
Global Spinal Muscular Atrophy (SMA) Market Insights, Epidemiology and Market Forecast Report 2017-2019 & 2028
Apr 25, 2019
Spinal Muscular Atrophy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Mar 19, 2019
SMA Treatment Market Size Worth $3.9 Billion by 2025 | CAGR 12.9%: Grand View Research, Inc.
Oct 03, 2018
Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients